Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells
暂无分享,去创建一个
Emilie Flaberg | Bruno Vanherberghen | L. Szekely | S. Eksborg | E. Klein | E. Carbone | B. Vanherberghen | Ennio Carbone | Eva Klein | Laszlo Markasz | Gyorgy Stuber | Laszlo Szekely | Eva Olah | Staffan Eksborg | Henriette Skribek | G. Stuber | É. Oláh | Laszlo Markasz | Henriette Skribek | E. Flaberg
[1] D. Alberts,et al. Antitumour activity and plasma kinetics of bleomycin by continuous and intermittent administration. , 1980, British Journal of Cancer.
[2] U. Tirelli,et al. Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] E. Gamelin,et al. Clinical pharmacokinetics of oxaliplatin: a critical review. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[4] E. Carbone,et al. Synergistic effect of IFN‐γ and human cytomegalovirus protein UL40 in the HLA‐E‐dependent protection from NK cell‐mediated cytotoxicity , 2001, European journal of immunology.
[5] J. Ritz,et al. Biology and clinical relevance of human natural killer cells. , 1990, Blood.
[6] R. Kiessling,et al. „Natural”︁ killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell , 1975, European journal of immunology.
[7] M. A. Sáez,et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma , 1997, Cancer.
[8] D. Davis,et al. The Actin Cytoskeleton Controls the Efficiency of Killer Ig-Like Receptor Accumulation at Inhibitory NK Cell Immune Synapses1 , 2004, The Journal of Immunology.
[9] A. Chang,et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. , 1985, The New England journal of medicine.
[10] M. Smyth,et al. KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity. , 2005, Experimental hematology.
[11] G. Trinchieri,et al. Biology of Natural Killer Cells , 1989, Advances in Immunology.
[12] A. Boddy,et al. Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration , 1996, Cancer Chemotherapy and Pharmacology.
[13] M. Tan,et al. High‐dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma , 2004, Cancer.
[14] O. N. Ozes,et al. Combination treatment of 2-chlorodeoxyadenosine and type I interferon on hairy cell leukemia-like cells: cytotoxic effect and MHC-unrestricted killer cell regulation. , 1993, Blood.
[15] Klas Kärre,et al. Spontaneous mutations in the human CMV HLA class I homologue UL18 affect its binding to the inhibitory receptor LIR‐1/ILT2/CD85j , 2006, European journal of immunology.
[16] R. Goldfarb,et al. Activation of multiple caspases and modification of cell surface fas (CD95) in proteasome inhibitor‐induced apoptosis of rat natural killer cells , 2003, Journal of cellular biochemistry.
[17] A. Boddy,et al. Pharmacokinetics of Dactinomycin in a Pediatric Patient Population: a United Kingdom Children's Cancer Study Group Study , 2005, Clinical Cancer Research.
[18] H. Klingemann. Cellular therapy of cancer with natural killer cells: will it ever work? , 2001, Journal of hematotherapy & stem cell research.
[19] N. Hanna,et al. Synergistic antitumor effects of topoisomerase inhibitors and natural cell-mediated cytotoxicity. , 1989, Cancer research.
[20] M. Caligiuri,et al. Immunotherapeutic approaches for hematologic malignancies. , 2004, Hematology. American Society of Hematology. Education Program.
[21] Simon C Watkins,et al. Nongranular proteolytic enzymes of rat IL‐2–activated natural killer cells. II. Purification and identification of rat A‐NKP 1 and A‐NKP 2 as constituents of the multicatalytic proteinase (proteasome) complex , 1994, Journal of cellular biochemistry.
[22] H. Kimura,et al. A Phase III randomized study of interleukin‐2 lymphokine‐activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma , 1997, Cancer.
[23] R. Danesi,et al. Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] Edward J. Lee,et al. Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[25] K. Ataga,et al. The Influence of Renal Function on Hydroxyurea Pharmacokinetics in Adults With Sickle Cell Disease , 2005, Journal of clinical pharmacology.
[26] M. Björkholm,et al. Pharmacokinetics of mitoxantrone, etoposide and cytosine arabinoside in leukemic cells during treatment of acute myelogenous leukemia--relationship to treatment outcome and bone marrow toxicity. , 1995, Leukemia research.
[27] I. Mononen,et al. Serious Neutropenia in ALL Patients Treated With L-Asparaginase May Be Avoided by Therapeutic Monitoring of the Enzyme Activity in the Circulation , 2002, Therapeutic drug monitoring.
[28] R. Goldfarb,et al. Nongranular proteolytic enzymes of rat IL-2-activated natural killer cells. I. Subcellular localization and functional role. , 1992, Journal of immunology.
[29] S. Clarke,et al. Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[30] M. Martelli,et al. Natural killer cell alloreactivity for leukemia therapy. , 2005, Journal of immunotherapy.
[31] P. Katz,et al. Mechanisms of human cell-mediated cytotoxicity. III. Dependence of natural killing on microtubule and microfilament integrity. , 1982, Journal of immunology.
[32] R. Gascoyne,et al. Phase II Study of Oral Vinorelbine in First-Line Advanced Breast Cancer Chemotherapy , 2003 .
[33] M. Hanada,et al. Cellular immunosuppression in children with acute lymphoblastic leukemia: Effect of consolidation chemotherapy , 2005, Cancer Immunology, Immunotherapy.
[34] Lewis L Lanier,et al. NK cell recognition. , 2005, Annual review of immunology.
[35] R. Goldfarb,et al. Non-granular proteolytic enzymes of rat interleukin-2-activated natural killer cells. III. Enhancement of A-NKP 1, 2, and 3 proteolytic activities (cleaving after Arg, Phe and Pro) in response to interleukin-2. , 1995, Natural immunity.
[36] R. Shanks,et al. Can severe vincristine neurotoxicity be prevented? , 2004, Cancer Chemotherapy and Pharmacology.
[37] R. Millikan,et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] B. Comin-Anduix,et al. Immunosensitization of Tumor Cells to Dendritic Cell-Activated Immune Responses with the Proteasome Inhibitor Bortezomib (PS-341, Velcade)1 , 2006, The Journal of Immunology.
[39] R. Goldfarb,et al. Accumulation of adoptively transferred A-NK cells in murine metastases: kinetics and role of interleukin-2. , 1994, In vivo.
[40] Adelheid Cerwenka,et al. Natural killer cells, viruses and cancer , 2001, Nature Reviews Immunology.
[41] S. Eksborg,et al. Liquid chromatographic monitoring of daunorubicin and daunorubicinol in plasma from leukemic patients treated with daunorubicin or the daunorubicin-DNA complex , 2004, Cancer Chemotherapy and Pharmacology.
[42] S. Natsugoe,et al. Prognostic value of intratumoral natural killer cells in gastric carcinoma , 2000, Cancer.
[43] S. Gruber,et al. Pharmacokinetics of 6-thiouric acid and 6-mercaptopurine in renal allograft recipients after oral administration of azathioprine , 2004, European Journal of Clinical Pharmacology.
[44] G. Juliusson,et al. Pharmacokinetics of cladribine in plasma and its 5'-monophosphate and 5'-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[45] J. Verweij,et al. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin) , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[46] J. Mcgregor,et al. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis. , 1990, Cancer research.
[47] Roberto Canaparo,et al. Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. , 2004, Pharmacological research.
[48] L. Moretta,et al. Killer immunoglobulin-like receptors. , 2004, Current opinion in immunology.
[49] Hein Putter,et al. Down-Regulation of HLA-A Expression Correlates with a Better Prognosis in Colorectal Cancer Patients , 2002, Laboratory Investigation.
[50] S. Steinberg,et al. A Phase I/II Study of Infusional Vinblastine with the P-Glycoprotein Antagonist Valspodar (PSC 833) in Renal Cell Carcinoma , 2004, Clinical Cancer Research.
[51] E. Kimby,et al. Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[52] A. Viel,et al. High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. , 1999, The American journal of pathology.
[53] Daniel J Weisdorf,et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. , 2002, Blood.
[54] M. Caligiuri,et al. New developments in anti-tumor efficacy and malignant transformation of human natural killer cells , 2003, Current opinion in hematology.
[55] C. Le,et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. , 2005, Blood.
[56] D. Newell,et al. A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve , 2009, Cancer Chemotherapy and Pharmacology.
[57] M. Caligiuri,et al. Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing , 1998, Cancer Immunology, Immunotherapy.
[58] R. Hubbard,et al. Lymphocyte subset infiltration patterns and HLA antigen status in colorectal carcinomas and adenomas. , 1996, Gut.
[59] T. Delozier,et al. Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.